Credit Suisse raised its target price for Jinxin Fertility (01951) to HK$15.12 from HK$12.25 and maintained its "outperform" rating.
The research house said the target price hike was based on management's reiteration on M&A expansion, increased margin from optimised revenue mix in the Xinan hospital, and the positive impact from restructuring in the Zhongshan hospital.
Jinxin reiterated its ability to maintain high success rates at each of its hospitals, achieving 20% top-line growth across its hospital network and continuing to seek M&A opportunities where it can add value to existing businesses and that it will focus on targets that have strong regional market potential.
Credit Suisse lifted its 2019-21 EPS forecasts by 3-7%.
15/10/2019 09:35
{I-bank focus}CS raises Jinxin Fertility (01951) to HK$15.12
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
